Skip header and navigation

2 records – page 1 of 1.

A 3-year follow-up after anterior colporrhaphy compared with collagen-coated transvaginal mesh for anterior vaginal wall prolapse: a randomised controlled trial.

https://arctichealth.org/en/permalink/ahliterature272920
Source
BJOG. 2016 Jan;123(1):136-42
Publication Type
Article
Date
Jan-2016
Author
M. Rudnicki
E. Laurikainen
R. Pogosean
I. Kinne
U. Jakobsson
P. Teleman
Source
BJOG. 2016 Jan;123(1):136-42
Date
Jan-2016
Language
English
Publication Type
Article
Keywords
Collagen
Denmark - epidemiology
Dyspareunia - epidemiology - etiology
Female
Finland - epidemiology
Follow-Up Studies
Gynecologic Surgical Procedures - instrumentation - methods
Humans
Norway - epidemiology
Pelvic Organ Prolapse - epidemiology - surgery
Prospective Studies
Quality of Life
Surgical Mesh
Surveys and Questionnaires
Sweden - epidemiology
Treatment Outcome
Vagina - surgery
Abstract
To compare the 1-year (previously published) and 3-year objective and subjective cure rates, and complications, related to the use of a collagen-coated transvaginal mesh for anterior vaginal wall prolapse against a conventional anterior repair.
Randomised controlled study.
Six departments of obstetrics and gynaecology in Norway, Sweden, Finland, and Denmark.
A total of 138 women, of 55 years of age or older, admitted for stage =2 anterior vaginal wall prolapse.
The women scheduled for primary anterior vaginal wall prolapse surgery were randomised between conventional anterior colporrhaphy and surgery with a collagen-coated prolene mesh. All patients were evaluated using the Pelvic Organ Prolapse Quantification (POP-Q) assessment before and after surgery. Symptoms related to pelvic organ prolapse were evaluated using the Pelvic Floor Impact Questionnaire (PFIQ-7) and the Pelvic Floor Distress Inventory (PFDI-20).
Objective cure, defined as POP-Q stage
PubMed ID
26420345 View in PubMed
Less detail

Anterior colporrhaphy compared with collagen-coated transvaginal mesh for anterior vaginal wall prolapse: a randomised controlled trial.

https://arctichealth.org/en/permalink/ahliterature106735
Source
BJOG. 2014 Jan;121(1):102-10; discussion 110-1
Publication Type
Article
Date
Jan-2014
Author
M. Rudnicki
E. Laurikainen
R. Pogosean
I. Kinne
U. Jakobsson
P. Teleman
Author Affiliation
Department of Obstetrics and Gynaecology, Roskilde University Hospital, Roskilde, Denmark.
Source
BJOG. 2014 Jan;121(1):102-10; discussion 110-1
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Collagen
Cystocele - surgery
Denmark
Female
Finland
Humans
Middle Aged
Norway
Quality of Life
Questionnaires
Sexuality
Surgical Mesh
Sweden
Treatment Outcome
Vagina - surgery
Abstract
To investigate the anatomical cure rate and complications related to collagen-coated mesh for cystocele, compared with a conventional anterior colporrhaphy.
A randomised controlled study.
Six departments of obstetrics and gynaecology in Norway, Sweden, Finland, and Denmark.
Women aged 55 years or older, referred for surgery with a prolapse of the anterior vaginal wall of stage 2 or higher.
Women scheduled for primary cystocoele surgery were randomised to either anterior colporrhaphy or a collagen-coated Prolene mesh. Power analysis indicated that 130 patients had to be randomised. All patients were evaluated using the Pelvic Organ Prolapse-Quantification (POP-Q) measurement. Quality of life, symptoms, and sexual function were evaluated using the Pelvic Floor Impact Questionnaire, the Pelvic Floor Distress Inventory, and the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire.
The primary outcome was objective cure, defined as prolapse below POP-Q stage 2 at the 12-months follow-up. Secondary outcomes were quality of life, symptoms, and presence (or not) of complications.
In total, 161 women were randomised to either anterior colporrhaphy or mesh (participant ages 64.9 ± 6.4 years versus 64.7 ± 6.6 years, respectively; mean ± SD). The objective cure rate was 39.8% (95% CI 28.6-50.9%) in the anterior colporrhaphy group, compared with 88.1% (95% CI 80.7-95.6%) in the mesh group (P
PubMed ID
24118844 View in PubMed
Less detail